Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose: Patients with rheumatoid arthritis (RA) who have muscle weakness and stiff or painful joints might be at increased risk of falling. The present study prospectively determines the incidence of falls and their risk factors in patients with RA who participated in the TOMORROW (TOtal Management Of Risk factors in Rheumatoid arthritis patients to lOW er morbidity and mortality; clinical trial registration number: UMIN000003876) study that was started in 2010.
Methods: We evaluated anthropometric parameters, muscle volume, bone mineral density (BMD), disease activity, general health status and the occurrence of falls for a period of two years in 202 patients with RA ( mean age: 58.4 years, 54% administered with biological agents) and 202 age- and sex-matched healthy volunteers (HV, mean age: 57.4 years).
Results: Among the patients with RA and HV, 29.6% and 26.7% respectively reported one or more falls during two years. These values did not significantly differ in the two groups. The fall group had higher age, lower BMD (p<0.01), higher whole % Fat mass (p<0.01) and tended to have induced walking time. After adjusting for risk factors of falls such as age, gender, smoking and BMI, multiple logistic regression analysis identified that a history of falls was the most significant parameter associated with falls (odds ratio: 2.39, p=0.001) (Table 1). The RA group also had lower whole muscle volume (37.2 vs. 39.6 kg; p = 0.001), leg BMD (0.967 vs. 1.031 mg/cm3; p < 0.001) and shorter exercise periods than HV, but none of these were associated with rates of falling. Furthermore, fall risk did not significantly and linearly increase with disease duration, disease activity score and physical status among the patients with RA.
Conclusion:
We concluded that the fall rate is not higher in patients with RA than in healthy volunteers and that only a history of falls plays a role in increasing the risk of falls.
Disclosure:
K. Mamoto,
None;
T. Koike,
Chugai Pharmaceutical,
2,
Eli Lilly Japan,
8,
Novartis Pharmaceutical Corporation,
2,
Teijin Pharma,
8,
Bristol-Myers Squibb,
5,
Ono Pharmaceutical,
8,
Santen Pharmaceutical,
8,
Eisai,
8,
Abbott Japan,
8,
Mitsubishi Tanabe Pharma Corporation,
2,
Takeda Pharmaceutical,
8,
Astellas Pharma Inc.,
8,
Pfizer Japan Inc.,
8,
Janssen Pharmaceutical,
2,
Asahi Kasei Pharma Corporation,
8,
Daiichi Sankyo Company,
2;
T. Okano,
None;
A. Kamiyama,
None;
Y. Sugioka,
None;
M. Tada,
None;
H. Nakamura,
None.
« Back to 2012 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-falling-is-equivalent-between-patients-with-rheumatoid-arthritis-and-healthy-individuals-the-tomorrow-study/